The estimated Net Worth of Robert Eugene Watson is at least $846 mil dollars as of 8 May 2024. Mr. Watson owns over 20,000 units of Cel-Sci stock worth over $28,829 and over the last 14 years he sold CVM stock worth over $0. In addition, he makes $816,852 as Independent Director at Cel-Sci.
Sign up
Mr. Watson CVM stock SEC Form 4 insiders trading
Robert has made over 14 trades of the Cel-Sci stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of CVM stock worth $27,800 on 8 May 2024.
The largest trade he's ever made was exercising 50,000 units of Cel-Sci stock on 31 January 2011 worth over $500. On average, Robert trades about 6,815 units every 173 days since 2011. As of 8 May 2024 he still owns at least 24,431 units of Cel-Sci stock.
You can see the complete history of Mr. Watson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Watson biography
Robert E. Watson is Independent Director of the Company. Mr. Watson is the President and CEO of Juvare, LLC (formerly Intermedix, Inc.) since July 2017. Immediately prior to joining Intermedix, now Juvare, he was the President and Chief Growth Officer of NantHealth, Inc. (Nasdaq: NH) from January 2015 to May 2017. Prior to NantHealth, he was President and CEO of Streamline Health, Inc. (Nasdaq: STRM) from January 2011 to January 2015. Mr. Watson has over 35 years of experience in the healthcare information technology industry as a CEO, board member and advisor to multiple healthcare information technology companies. He has participated in over 75 acquisitions, raised nearly $750 million in capital, completed three public offerings and successfully sold four companies. Mr. Watson holds a MBA from the Wharton School of Business at the University of Pennsylvania and a BA degree from Syracuse University. Mr. Watson’s business experience and educational background makes him qualified to serve as a director of CEL-SCI.
What is the salary of Robert Watson?
As the Independent Director of Cel-Sci, the total compensation of Robert Watson at Cel-Sci is $816,852. There are 6 executives at Cel-Sci getting paid more, with Geert Kersten having the highest compensation of $4,546,360.
How old is Robert Watson?
Robert Watson is 62, he's been the Independent Director of Cel-Sci since 2017. There are 10 older and 1 younger executives at Cel-Sci. The oldest executive at Cel-Sci Corp. is Dr. Daniel H. Zimmerman Ph.D., 80, who is the Sr. VP of Research & Cellular Immunology.
What's Robert Watson's mailing address?
Robert's mailing address filed with the SEC is 245 N. HIGHLAND AVE NE, SUITE 230-296, ATLANTA, GA, 30307.
Insiders trading at Cel-Sci
Over the last 21 years, insiders at Cel-Sci have traded over $3,069,559 worth of Cel-Sci stock and bought 1,693,350 units worth $1,328,136 . The most active insiders traders include Clara Maximilian De, Geert R Kersten y Eyal Talor. On average, Cel-Sci executives and independent directors trade stock every 50 days with the average trade being worth of $42,938. The most recent stock trade was executed by Robert Eugene Watson on 8 May 2024, trading 20,000 units of CVM stock currently worth $27,800.
What does Cel-Sci do?
cel-sci corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. the company's lead investigational immunotherapy is multikine, which is under phase iii clinical trial for the treatment of head and neck cancer. its ligand epitope antigen presentation system (leaps), a pre-clinical patented t-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. the company also develops leaps-h1n1-dc; cel-2000 and cel-4000 are product candidates for the treatment of rheumatoid arthritis; and leaps cov-19, a product candidate to treat covid-19 coronavirus. cel-sci corporation has a collaboration agreement with the university of georgia's center for vaccines and immunology to develop leaps covid-19 immunotherapy. the company was founded in 1983 and is headquartered in vienna, virginia.
What does Cel-Sci's logo look like?
Complete history of Mr. Watson stock trades at Streamline Health Solutions, Inc y Cel-Sci
Cel-Sci executives and stock owners
Cel-Sci executives and other stock owners filed with the SEC include:
-
Geert Kersten,
Chief Executive Officer, Treasurer, Director -
Patricia Prichep,
Senior Vice President - Operations, Corporate Secretary -
Eyal Talor,
Chief Scientific Officer -
Daniel Zimmerman,
Senior Vice President - Research, Cellular Immunology -
John Cipriano,
Senior Vice President - Regulatory Affairs -
Peter Young,
Independent Director -
Robert Watson,
Independent Director -
Bruno Baillavoine,
Independent Director -
Geert R. Kersten,
CEO, Principal Accounting & Financial Officer, Treasurer and Director -
Geert R. Kersten Esq.,
Chief Exec. & Financial Officer, Treasurer and Director -
Dr. Eyal Talor Ph.D.,
Chief Scientific Officer -
Patricia B. Prichep,
Sr. VP of Operations & Corp. Sec. -
Dr. Daniel H. Zimmerman Ph.D.,
Sr. VP of Research & Cellular Immunology -
John Cipriano,
Sr. VP of Regulatory Affairs -
Clara Maximilian De,
President -
Alexander G Esterhazy,
Director -
C Richard Kinsolving,
Director -
Gail K Naughton,
Director